GlobeNewsWire
01 Sept 2026, 19:53 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Regeneron's Phase 3 Trial of Fianlimab failed to reach statistical significance for its primary endpoint of improvement in progression-free survival (PFS). — The failure of a Phase 3 clinical trial is a major negative catalyst for a pharmaceutical company's pipeline and future revenue projections.
-0.80The Portnoy Law Firm has initiated a class action lawsuit against Regeneron alleging false and misleading statements regarding the Phase III Fianlimab-Libtayo Study. — Legal challenges and allegations of corporate wrongdoing create additional financial liability and reputational risk.
-0.30Regeneron altered the Phase III Fianlimab-Libtayo Study to expand the number of patients eligible for analysis of progression-free survival. — Changing trial parameters mid-study often signals difficulty in meeting original endpoints, leading to investor skepticism.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
49m ago
